Agensys and Merck Announce Agreement to Co-Develop and Commercialize a Novel Antibody for Cancer Therapy
19-Oct-2005 -
Agensys, Inc., a cancer biotechnology company, and Merck & Co., Inc. announced that they have formed a global alliance to jointly develop and commercialize AGS-PSCA, Agensys' fully human monoclonal antibody (MAb) to Prostate Stem Cell Antigen (PSCA).
The agreement grants Merck worldwide rights ...
advanced androgen-dependent carcinoma of the prostate
biotechnology
cancer therapy
+5